A multi-center adjuvant trial of outpatient moderate-dose bolus interleukin-2 [aldesleukin] for renal cancer
Latest Information Update: 18 Sep 2021
At a glance
- Drugs Aldesleukin (Primary)
- Indications Renal cell carcinoma
- Focus Therapeutic Use
- 06 Nov 2013 Biomarkers information updated
- 17 Sep 2005 New trial record.